Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Performance

Shares of BCLI stock opened at $1.56 on Tuesday. The stock has a fifty day simple moving average of $1.80 and a two-hundred day simple moving average of $2.15. The firm has a market capitalization of $8.90 million, a PE ratio of -0.33 and a beta of 0.74. Brainstorm Cell Therapeutics has a 52-week low of $1.05 and a 52-week high of $11.89.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.